Josh Schimmer
Co-host of Biotech Hangout. Offers insights on the biotech sector, investor sentiment, and market dynamics.
Top 3 podcasts with Josh Schimmer
Ranked by the Snipd community
Apr 30, 2024 • 59min
Episode 99
Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.
Jan 4, 2024 • 60min
Episode 82
Biotech Hangout welcomes biotech analysts Josh Schimmer, Tim Opler, Chris Garabedian, Dawn Bell, and guest host Eric Schmidt. They cover topics such as the JPM year in review, XBI performance, Abbvie's acquisition of Cerevel, big GLP-1 deal from Roche and Carmot, AstraZeneca/IRA case, three big investors days from J&J, Sanofi and Neurocrine Biosciences, CVS's drug coverage update, and Eyepoint Pharmaceutical's wet AMD data.
Oct 16, 2023 • 60min
Episode 76
Biotech Hangout's Daphne Zohar, Brad Loncar, Josh Schimmer, Mike Yee & Tim Opler cover the big news: BMS' acquisition of Mirati Therapeutics, 14 biotech acquisitions over $1B, and Illumina ordered to sell Grail after acquisition deal. They discuss data from Akero, Alnylam, Ventyx, Merck, Novo Nordisk, Immunic, and PMV Pharmaceuticals. Takeaways from Jefferies CNS Day and HLTH 2023 are shared.
